$510 Million is the total value of Opaleye Management Inc.'s 47 reported holdings in Q4 2019. The portfolio turnover from Q3 2019 to Q4 2019 was 32.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EPZM | Buy | EPIZYME INC | $34,051,000 | +141.8% | 1,384,200 | +1.4% | 6.68% | +31.2% |
| Buy | APTOSE BIOSCIENCES INC | $23,162,000 | +1443.1% | 4,085,000 | +467.4% | 4.54% | +737.0% | |
| CDXS | Buy | CODEXIS INC | $22,286,000 | +20.4% | 1,400,000 | +3.7% | 4.37% | -34.7% |
| FTSV | Buy | FORTY SEVEN INC | $22,126,000 | +710.8% | 562,000 | +32.2% | 4.34% | +339.8% |
| STXS | Buy | STEREOTAXIS INC | $22,025,000 | +54.2% | 4,112,500 | +1.0% | 4.32% | -16.3% |
| TPTX | Buy | TURNING POINT THERAPEUTICS INC | $21,210,000 | +96.2% | 340,500 | +18.4% | 4.16% | +6.5% |
| OCUL | Buy | OCULAR THERAPEUTIX INC | $20,175,000 | +139.2% | 5,107,500 | +84.1% | 3.96% | +29.8% |
| IMMY | Sell | HARROW HEALTH | $18,205,000 | +36.7% | 2,340,000 | -1.3% | 3.57% | -25.8% |
| EIDX | Buy | EIDOS THERAPEUTICS INC | $18,109,000 | +64.8% | 315,550 | +3.3% | 3.55% | -10.6% |
| BOLD | Buy | AUDENTES THERAPEUTICS INC | $17,473,000 | +118.2% | 292,000 | +2.5% | 3.43% | +18.4% |
| NLTX | Buy | NEOLEUKIN THERAPEUTICS INC | $17,018,000 | +500.1% | 1,381,300 | +38.8% | 3.34% | +225.4% |
| QURE | Buy | UNIQURE NV | $15,049,000 | +86.5% | 210,000 | +2.4% | 2.95% | +1.2% |
| AMRN | Buy | AMARIN CORP PLCsponsored adr | $14,258,000 | +45.8% | 665,000 | +3.1% | 2.80% | -20.9% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $13,973,000 | +79.0% | 224,500 | -2.4% | 2.74% | -2.9% |
| ITCI | Buy | INTRA CELLULAR THERAPIES INC | $13,950,000 | +998.4% | 406,600 | +139.2% | 2.74% | +496.3% |
| CCXI | Buy | CHEMOCENTRYX INC | $13,846,000 | +921.1% | 361,600 | +80.8% | 2.72% | +454.5% |
| AXGN | AXOGEN INC | $12,523,000 | +49.5% | 700,000 | 0.0% | 2.46% | -18.9% | |
| CERC | Buy | CERECOR INC | $11,808,000 | +64.2% | 2,190,674 | +0.2% | 2.32% | -10.9% |
| ODT | Buy | ODONATE THERAPEUTICS INC | $11,520,000 | +26.4% | 355,000 | +1.4% | 2.26% | -31.4% |
| ETON | Buy | ETON PHARMACEUTICALS INC | $10,580,000 | +43.7% | 1,469,456 | +26.1% | 2.08% | -22.0% |
| XOMA | Sell | XOMA CORP DEL | $10,195,000 | +37.9% | 373,450 | -0.4% | 2.00% | -25.2% |
| ATXI | Buy | AVENUE THERAPEUTICS INC | $9,936,000 | +75.0% | 1,035,000 | +8.7% | 1.95% | -5.0% |
| Buy | FORTRESS BIOTECH INC | $9,831,000 | +321.2% | 3,825,100 | +131.1% | 1.93% | +128.6% | |
| PTCT | Buy | PTC THERAPEUTICS INC | $9,174,000 | +42.8% | 191,000 | +0.5% | 1.80% | -22.5% |
| BHVN | Buy | BIOHAVEN PHARMACEUTICAL HLDG | $8,983,000 | +34.6% | 165,000 | +3.1% | 1.76% | -27.0% |
| ACAD | Buy | ACADIA PHARMACEUTICALS INC | $8,834,000 | +22.7% | 206,500 | +3.2% | 1.73% | -33.4% |
| FLXN | Buy | FLEXION THERAPEUTICS INC | $8,601,000 | +497.7% | 415,500 | +295.7% | 1.69% | +224.6% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $8,001,000 | +3.7% | 100,000 | -4.8% | 1.57% | -43.7% |
| ZYME | Buy | ZYMEWORKS INC | $7,956,000 | +88.7% | 175,000 | +2.9% | 1.56% | +2.4% |
| EDAP | Buy | EDAP TMS SAsponsored adr | $7,908,000 | +487.1% | 1,785,000 | +495.0% | 1.55% | +218.7% |
| TCDA | Sell | TRICIDA INC | $7,303,000 | +21.3% | 194,000 | -0.5% | 1.43% | -34.2% |
| MGTA | Buy | MAGENTA THERAPEUTICS INC | $6,728,000 | +70.3% | 449,950 | +16.9% | 1.32% | -7.6% |
| CRNX | Buy | CRINETICS PHARMACEUTICALS INC | $6,676,000 | +114.5% | 266,100 | +28.6% | 1.31% | +16.3% |
| RARX | RA PHARMACEUTICALS INC | $6,655,000 | +98.4% | 141,800 | 0.0% | 1.31% | +7.7% | |
| TGTX | Sell | TG THERAPEUTICS INC | $6,434,000 | +87.1% | 579,651 | -5.4% | 1.26% | +1.4% |
| FGEN | Sell | FIBROGEN INC | $6,262,000 | +12.9% | 146,000 | -2.7% | 1.23% | -38.7% |
| ACHN | New | ACHILLION PHARMACEUTICALS INC | $4,583,000 | – | 760,000 | +100.0% | 0.90% | – |
| AQST | New | AQUESTIVE THERAPEUTICS INC | $4,298,000 | – | 738,500 | +100.0% | 0.84% | – |
| KDMN | New | KADMON HOLDINGS INC | $4,260,000 | – | 940,373 | +100.0% | 0.84% | – |
| RDUS | Buy | RADIUS HEALTH INC | $3,387,000 | +75.4% | 168,000 | +124.0% | 0.66% | -4.7% |
| QTRX | Sell | QUANTERIX CORP | $3,124,000 | -23.1% | 132,200 | -28.5% | 0.61% | -58.3% |
| RYTM | New | RHYTHM PHARMACEUTICALS INC | $2,537,000 | – | 110,500 | +100.0% | 0.50% | – |
| TELA | New | TELA BIO INC | $2,266,000 | – | 175,000 | +100.0% | 0.44% | – |
| MGNX | New | MACROGENICS INC | $2,181,000 | – | 200,500 | +100.0% | 0.43% | – |
| PRTO | Buy | PROTEON THERAPEUTICS INC | $75,000 | +435.7% | 188,144 | +248.4% | 0.02% | +200.0% |
| FENC | New | FENNEC PHARMACEUTICALS INC | $78,000 | – | 12,000 | +100.0% | 0.02% | – |
| BLRX | BIOLINERX LTDsponsored adr | $38,000 | -13.6% | 16,667 | 0.0% | 0.01% | -56.2% | |
| ASMB | Exit | ASSEMBLY BIOSCIENCES INC | $0 | – | -50,000 | -100.0% | -0.18% | – |
| VRML | Exit | VERMILLION INC | $0 | – | -1,265,000 | -100.0% | -0.24% | – |
| CBAY | Exit | CYMABAY THERAPEUTICS INC | $0 | – | -140,000 | -100.0% | -0.26% | – |
| SBBP | Exit | STRONGBRIDGE BIOPHARMA PLC | $0 | – | -490,000 | -100.0% | -0.42% | – |
| NXTC | Exit | NEXTCURE INC | $0 | – | -85,000 | -100.0% | -0.95% | – |
| THOR | Exit | SYNTHORX INC | $0 | – | -180,000 | -100.0% | -1.06% | – |
| SWAV | Exit | SHOCKWAVE MED INC | $0 | – | -160,000 | -100.0% | -1.73% | – |
| Exit | CYTOKINETICS | $0 | – | -650,000 | -100.0% | -2.68% | – | |
| CARA | Exit | CARA THERAPEUTICS INC | $0 | – | -440,000 | -100.0% | -2.91% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CODEXIS INC | 39 | Q3 2023 | 10.9% |
| CHIMERIX INC | 31 | Q3 2022 | 16.4% |
| XOMA CORP DEL | 27 | Q3 2023 | 3.6% |
| FIBROGEN INC | 26 | Q1 2021 | 6.8% |
| BIOLINERX LTD (Does not reflect a reverse stock split effectuated after June 30, 2019) | 26 | Q1 2020 | 2.4% |
| OCULAR THERAPEUTIX INC | 24 | Q3 2023 | 17.6% |
| AXOGEN INC | 20 | Q4 2019 | 18.7% |
| ETON PHARMACEUTICALS INC | 20 | Q3 2023 | 5.6% |
| AMARIN CORP PLC | 20 | Q4 2020 | 6.6% |
| IMPRIMIS PHARMACEUTICALS INC | 19 | Q1 2020 | 5.9% |
View Opaleye Management Inc.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CHIMERIX INCSold out | February 13, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc. | January 23, 2023 | 1,560,000 | 3.6% |
| TELA Bio, Inc. | June 10, 2022 | 1,557,500 | 10.7% |
| Gemini Therapeutics, Inc. /DESold out | February 01, 2022 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | January 26, 2022 | 0 | 0.0% |
| AVENUE THERAPEUTICS, INC. | February 12, 2021 | 9 | 11.0% |
| Cardiff Oncology, Inc. | February 12, 2021 | 9 | 11.0% |
| EDAP TMS SA | February 12, 2021 | 9 | 11.0% |
| Fortress Biotech, Inc. | February 12, 2021 | 9 | 11.0% |
| Gemini Therapeutics, Inc. /DE | February 12, 2021 | 9 | 11.0% |
View Opaleye Management Inc.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-25 |
| 4 | 2024-04-24 |
| 4 | 2024-04-19 |
| SC 13G/A | 2024-04-09 |
| SC 13G | 2024-04-08 |
| 4 | 2024-03-28 |
| 4 | 2024-03-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Opaleye Management Inc.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.